Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2589 - An epidemiological insight into epithelioid sarcoma (ES): the open issue of distal-type (DES) versus proximal-type (PES)

Date

11 Sep 2017

Session

Poster display session

Presenters

Anna Maria Frezza

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

A.M. Frezza1, L. Botta2, S. Pasquali3, S. Stacchiotti1, A. Gronchi3, P.G.G. Casali1, A. Trama2, W.G. Rarecarenet2

Author affiliations

  • 1 Adult Mesenchymal Tumour And Rare Cancer Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Evaluative Epidemiology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Department Of Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
More

Resources

Abstract 2589

Background

ES is a rare sarcoma with distinctive pathologic and clinical features as well as the potential to respond to new targeted agents. We used the RARECAREnet and the SEER18 cancer registry (CR) databases (DB) to highlight the epidemiological hallamrks of ES in the EU and in the US.

Methods

The ICD-O3 code 8804 applies both to the DES and PES. Thus we broke down the primary sites using the ICD-O3 topography codes, to separate the anatomically proximal and distal forms, as a partial surrogate for the two entities of DES and PES. Incidence rate (IR), world-age adjusted IR and relative survival (RS) were calculated for ES patients diagnosed in the period 2000-07 and followed-up at least up to 31st Dec 2008. RS was estimated by the Ederer II method. 497 new cases of ES were identified from available registries in the EU, 301 in the US.

Results

Crude IR was 0.03/100,000 in the EU and 0.05/100,000 in the US. Age-adjusted IR were 0.02/100,000 and 0.05/100,000 respectively. M:F ratio was 1.6 in both sets of registries. Mean age at diagnosis was 46 in the EU and 44 yrs in the US. IR increased with age (higher in > 75-yr patients). IR in the childhood population ( 40EU: 0.03 US: 0.06EU: 39% (32-46) US: 39% (30-47)EU: 49% (37-61) US: 62% (45-75)EU: 33% (25-41) US: 26% (17-35)

Conclusions

ES is a very rare cancer, exceedingly low in childhood. Prognosis is serious, making the identification of new treatments a priority. New targeted agents are currently under study. However, the distinction between DES and PES is likely to be of major prognostic significance. In fact, using anatomical location as a proxy, though inappropriate, we could see clear-cut differences in the epidemiological outcome. An effort to stratify ES patients by their pathologic subtype is warranted in all studies, all the more on new agents.

Clinical trial identification

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale Tumori Milano

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.